FUS Protein in Amyotrophic Lateral Sclerosis
Introduction
Fus Protein In Amyotrophic Lateral Sclerosis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Fused in Sarcoma (FUS) is an RNA-binding protein that plays critical roles in RNA metabolism, including transcription, splicing, transport, and translation. Mutations in the FUS gene cause approximately 5-10% of familial ALS cases and a smaller percentage of sporadic ALS. The FUS protein is pathologically characterized by the formation of stress granules and cytoplasmic inclusions in affected motor [neurons](/entities/neurons). [@ling2013]
Mermaid diagram (expand to render)
FUS Protein Structure
The FUS protein contains several functional domains: [@bosco2010]
- N-terminal low-complexity domain (LCD): Prion-like domain involved in phase separation
- RNA recognition motif (RRM): Binds RNA sequences
- Zinc finger domain (ZF): RNA binding
- Nuclear localization signal (NLS): Nuclear import
- C-terminal proline-rich region: Protein interactions
Pathogenic Mutations
Over 50 ALS-associated mutations have been identified in FUS, with clustering in the: [@vance2009]
- Nuclear localization signal (NLS): R521C, R521H, R521G, R525L, R525Q
- C-terminus: P525L, R514S, R514G
- Low-complexity domain: G156E, G187V, G191V
The most common mutation is R521C, accounting for approximately 3% of all ALS cases. [@dormann2010]
Pathogenic Mechanisms
1. Nuclear Import Defects
FUS mutations disrupt the nuclear localization signal, impairing nuclear import: [@ito2024]
- Mutations in NLS reduce binding to importin-α/β
- Cytoplasmic accumulation of mutant FUS
- Loss of nuclear FUS function
- Disruption of nuclear RNA processing
FUS is recruited to stress granules under cellular stress: [@kwiatkowski2009]
- Mutant FUS forms persistent stress granules
- Sequestration of translation initiation factors
- Inhibition of global translation
- Stress granule persistence leads to cellular toxicity
3. RNA Splicing Dysregulation
FUS regulates alternative splicing of many neuronal genes: [@naumann2019]
- Intron retention in target genes
- Exon skipping events
- Dysregulation of neuronal-specific splicing factors
- Aberrant splicing of synaptic proteins
4. Nucleocytoplasmic Transport Defects
FUS mutations disrupt nucleocytoplasmic transport: [@shiihashi2021]
- Disruption of nuclear pore function
- Impaired RNA export
- Cytoplasmic RNA accumulation
- Formation of RNA granules
5. Mitochondrial Dysfunction
FUS mutations affect mitochondrial health: [@shang2023]
- Reduced mitochondrial trafficking
- Impaired mitochondrial dynamics
- Increased [reactive oxygen species](/entities/reactive-oxygen-species)
- Mitochondrial membrane potential loss
6. Axonal Transport Defects
FUS is involved in axonal transport: [@liu2023]
- Disruption of mRNA transport in axons
- Impaired local protein synthesis
- Loss of synaptic protein expression
- Axonal degeneration
Disease Phenotypes
Juvenile ALS (onset <25 years)
- More aggressive disease course
- Often associated with P525L mutation
- Earlier respiratory involvement
Adult-onset ALS
- More common presentation
- Typically R521C mutation
- Median survival 2-5 years
FUS-ALS Phenotype
- Early onset compared to sporadic ALS
- Predominant lower motor neuron involvement
- Rapid progression
- Bulbar onset in some cases
Relationship to Other Proteinopathies
FUS vs. TDP-43 Overlap
- Both form cytoplasmic inclusions
- Shared mechanisms in RNA metabolism
- Some cases show both pathologies
- Different genetic causes
Differences from TDP-43
- FUS inclusions are more globular
- Less widespread cortical involvement
- More prominent motor neuron specificity
- Different stress granule dynamics
Therapeutic Strategies
1. Antisense Oligonucleotides (ASOs)
- Target FUS mRNA for degradation
- Reduce mutant FUS expression
- Preclinical promise in mouse models
- Clinical trials ongoing
2. Small Molecule Modulators
- Modulators of phase separation
- Stress granule disruptors
- Nuclear import enhancers
3. Gene Therapy
- AAV-delivered ASOs
- CRISPR-based approaches
- Viral vector delivery
4. Neuroprotective Strategies
- Mitochondrial protectants
- Antioxidant therapy
- Anti-inflammatory approaches
Biomarkers
Genetic
- FUS mutation testing
- Family history assessment
Protein-based
- FUS levels in CSF
- Phosphorylated FUS in blood
Imaging
- MR spectroscopy changes
- Diffusion tensor imaging abnormalities
Animal Models
- Transgenic FUS mice
- FUS knock-in models
- Zebrafish models
- Induced pluripotent stem cell (iPSC) models
Background
The study of Fus Protein In Amyotrophic Lateral Sclerosis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@tyzack2022]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@scekiczahirovic2021]
See Also
- [/mechanisms/app-processing](/mechanisms/app-processing)
- [/mechanisms/amyloid-aggregation](/mechanisms/amyloid-aggregation)
- [/mechanisms/mitochondrial-dysfunction-ad](/mechanisms/mitochondrial-dysfunction-ad)
- [ROS](/entities/ros)
- [/mechanisms/synaptic-dysfunction-ad](/mechanisms/synaptic-dysfunction)mechanisms/synaptic-dysfunction)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
Cross-References
- [Amyotrophic Lateral Sclerosis Mechanistic Pathway](/mechanisms/als-pathway)
- [TDP-43 Proteinopathy in ALS](/mechanisms/als-tdp43-pathology)
- [C9orf72 ALS Pathway](/mechanisms/als-c9orf72-pathway)
- [SOD1 ALS Pathway](/mechanisms/als-sod1-pathway)
- [Stress Granules in Neurodegeneration](/mechanisms/stress-granules)
- [RNA Metabolism in Neurodegeneration](/mechanisms/rna-metabolism)
Additional evidence sources: [@lenzi2022] [@akiyama2024]
Confidence Assessment
🔴 Low Confidence
| Dimension | Score |
|-----------|-------|
| Supporting Studies | 15 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 38%
Recent Research Updates (2024-2026)
- [Ho DM et al., Proc Natl Acad Sci U S A (2024 Jun 11)](https://pubmed.ncbi.nlm.nih.gov/38838021/)
- [Dash BP et al., Cells (2025 Sep 10)](https://pubmed.ncbi.nlm.nih.gov/41002383/)
- [Ismail M et al., Biology (Basel) (2024 Mar 26)](https://pubmed.ncbi.nlm.nih.gov/38666827/)
- [Naumann M et al., Adv Sci (Weinh) (2026 Jan 28)](https://pubmed.ncbi.nlm.nih.gov/41603250/)
Additional Reading
FUS Phase Separation and Condensate Biology
Liquid-Liquid Phase Separation
FUS undergoes liquid-liquid phase separation (LLPS) through its low-complexity domain:
- Multivalent interactions: The LCD contains multiple aromatic and glycine residues that mediate pi-pi and cation-pi interactions with RNA
- Concentration dependence: LLPS occurs above a critical concentration threshold
- Temperature sensitivity: Phase separation is temperature-dependent
- RNA modulation: RNA binding modulates FUS condensate properties
Dysregulation in ALS
ALS-associated FUS mutations alter phase separation behavior:
| Mutation Type | Effect on Phase Separation | Outcome |
|---------------|---------------------------|---------|
| NLS mutations | Increased cytoplasmic FUS | More stress granule recruitment |
| LCD mutations | Enhanced gelation | Solid-like aggregate formation |
| R521C | Slower dissolution | Persistent granules |
| P525L | Accelerated aggregation | Early onset disease |
Nuclear FUS Condensates
FUS also forms nuclear condensates with distinct functions:
- Nuclear speckles: FUS localizes to nuclear speckles involved in splicing
- transcription factories: FUS associates with active transcription sites
- Nucleolar organizer regions: FUS in rRNA transcription
Transportin Pathophysiology
Normal Transportin Function
Transportin (TRN1/KPNB1) is the nuclear import receptor for FUS:
- Binds FUS LCD domain
- Mediates nuclear import through nuclear pore complex
- Recycling between nucleus and cytoplasm
Dysfunction in FUS-ALS
ALS mutations disrupt transportin-mediated import:
- NLS mutations: Impair binding to importin-β
- Competition with importins: Arginine-rich DPRs (from C9orf72) can compete
- Saturation of import machinery: Overwhelmed capacity in disease
- Therapeutic target: Enhancing transportin function
Transcriptional Regulation
FUS directly regulates transcription:
- RNA polymerase II recruitment: Interacts with transcription factors
- Chromatin remodeling: Associates with chromatin modifiers
- Alternative promoter usage: Affects promoter selection
Splicing Functions
FUS regulates alternative splicing of neuronal transcripts:
| Target Gene | Function | Consequence of FUS Loss |
|-------------|----------|------------------------|
| UNC13A | Synaptic vesicle release | Impaired neurotransmission |
| MAPT | Tau isoforms | Altered microtubule function |
| GRM4 | Glutamate receptor | Excitotoxicity risk |
| BDNF | Neurotrophin | Survival deficits |
RNA Transport
FUS facilitates mRNA transport in neurons:
- Axonal mRNA localization: Critical for local translation
- Synaptic RNA targeting: Delivers transcripts to synapses
- dendritic branching: Affects dendrite morphology
- Activity-dependent translation: Couples neural activity to protein synthesis
FUS and Mitochondrial Dysfunction
Direct Mitochondrial Effects
FUS pathology affects mitochondria through multiple mechanisms:
- Mitochondrial trafficking impairment: FUS aggregates disrupt motor protein function
- Energy deficit: Reduced ATP production from impaired oxidative phosphorylation
- Calcium handling: Altered mitochondrial calcium buffering
- Apoptosis promotion: Pro-apoptotic factor release
Reactive Oxygen Species
FUS mutations lead to increased ROS:
- Mitochondrial ROS: Elevated superoxide production
- Oxidative stress: Damage to proteins, lipids, DNA
- Antioxidant response: Nrf2 pathway activation in some cases
- Feedback loops: ROS further promotes FUS aggregation
Non-Cell Autonomous Mechanisms
Astrocyte Reactivity
FUS pathology triggers astrocyte responses:
- Reactive astrocytosis: Upregulation of GFAP
- Secreted factors: Altered neurotrophic support
- Inflammatory cytokine release: IL-6, TNF-α
- glutamate uptake impairment: Excitotoxicity risk
Microglial Activation
Microglia contribute to disease progression:
- Chronic inflammation: Sustained pro-inflammatory state
- Phagocytic activity: Altered debris clearance
- TREM2 involvement: Risk gene effects in microglia
- Synaptic pruning: Enhanced elimination of synapses
Experimental Model Systems
Cellular Models
| Model | Advantages | Limitations |
|-------|------------|-------------|
| iPSC-derived neurons | Patient genetic background | Variable differentiation |
| Motor neuron cultures | Relevant cell type | Limited survival |
| Astrocyte co-culture | Non-cell autonomous effects | Complexity |
| Organoids | 3D structure | Variability |
Animal Models
| Model | Key Features | Research Use |
|-------|--------------|--------------|
| FUS transgenic mice | Mutant FUS expression | Disease mechanisms |
| FUS knock-in | Endogenous mutation | Physiological relevance |
| Zebrafish | Rapid development | Drug screening |
| Drosophila | Genetic tractability | Pathway studies |
Therapeutic Development
ASO Strategies
Antisense oligonucleotides targeting FUS:
- Mechanism: RNase H-mediated degradation of mutant FUS mRNA
- Delivery: Intrathecal administration to reach CNS
- Preclinical: Significant benefit in mouse models
- Challenges: Allele-specific targeting vs. total FUS reduction
Small Molecule Approaches
| Target | Approach | Stage |
|--------|----------|-------|
| Phase separation | Modulate LLPS | Preclinical |
| Nuclear import | Enhance importin function | Preclinical |
| Stress granules | Promote dissolution | Preclinical |
| Aggregation | Aggregation inhibitors | Preclinical |
Gene Therapy Vectors
- AAV serotypes: AAV9, AAVrh.10 for CNS delivery
- Promoter selection: Synapsin, GFAP for cell-type specificity
- Dose optimization: Balancing efficacy and toxicity
- Delivery routes: IV, intrathecal, intracerebral
Biomarker Development
Fluid Biomarkers
- FUS in CSF: Elevated in FUS-ALS
- Phospho-FUS: Disease-specific phosphorylation
- NfL: General neurodegeneration marker
Imaging Biomarkers
- MRI: Upper motor neuron involvement
- PET: In development for FUS pathology
- DTI: White matter tract integrity
Clinical Biomarkers
- EMG patterns: FUS-associated features
- Disease progression: Rapid progression marker
- Respiratory function: Early monitoring
References
[Deng H, Gao K, Jankovic J, The role of FUS gene in amyotrophic lateral sclerosis (2014)](https://pubmed.ncbi.nlm.nih.gov/24792956/)
[Ling SC, Polymenidou M, Cleveland DW, Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis (2013)](https://pubmed.ncbi.nlm.nih.gov/23931993/)
[Bosco DA, Lemay N, Ko HK, et al, Mutant FUS proteins that cause ALS incorporate into stress granules (2010)](https://pubmed.ncbi.nlm.nih.gov/20940136/)
[Vance C, Rogelj B, Hortobágyi T, et al, Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6 (2009)](https://pubmed.ncbi.nlm.nih.gov/19251628/)
[Dormann D, Rodde R, Edbauer D, et al, ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import (2010)](https://pubmed.ncbi.nlm.nih.gov/20606625/)
Ito D, Hatakeyama J, Kondo H, et al, Harnessing the therapeutic potential of FUS protein in ALS (2024)
[Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al, Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis (2009)](https://pubmed.ncbi.nlm.nih.gov/19251627/)
Naumann M, Peikert K, Günther R, et al, Phenotypes and malignancy risk of FUS mutations in amyotrophic lateral sclerosis (2019)
Shiihashi G, Ito D, Arai T, et al, FUS inclusions are the major pathological feature in ALS with FUS mutations (2021)
Shang Y, Huang EJ, Targeting FUS-mediated phase separation for ALS therapy (2023)
Liu Y, Niu L, Liu C, et al, Stress granule homeostasis in ALS/FTD (2023)
Tyzack GE, Luisier B, Taha DM, et al, Astrocyte reactivity in FUS-ALS (2022)
Scekic-Zahirovic J, Sissaoui S, Picot L, et al, Motor neuron degeneration in FUS-ALS mice (2021)
Lenzi J, De Santis R, Tieri V, et al, Different mutation profiles and clinical characteristics in FUS-ALS (2022)
Akiyama T, Warabi M, Kondo S, et al, Therapeutic targeting of FUS pathology (2024)